Abstract
Sumoylation has been implicated in a variety of cancers, suggesting that sumoylation manipulation could be one approach for regulating tumorgenesis. Ubc9 exerts a central function for the sumoylation pathway, interacting with almost all the partners required for sumoylation. The high-resolution structure available for Ubc9 as well as the recent determination of more interacting partner complex structures makes rational drug design that target Ubc9 possible. Structure-based virtual drug screening has been used increasingly as the first step of drug design to select potential lead templates. This review analyzes all the interfaces between Ubc9 and its binding partners while also highlighting the possible targeting sites on Ubc9 best suited for virtual screening and drug design.
Keywords: Sumoylation, Ubc9, virtual screen, structure
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design
Volume: 9 Issue: 1
Author(s): Xinyuan Duan, John O. Trent and Hong Ye
Affiliation:
Keywords: Sumoylation, Ubc9, virtual screen, structure
Abstract: Sumoylation has been implicated in a variety of cancers, suggesting that sumoylation manipulation could be one approach for regulating tumorgenesis. Ubc9 exerts a central function for the sumoylation pathway, interacting with almost all the partners required for sumoylation. The high-resolution structure available for Ubc9 as well as the recent determination of more interacting partner complex structures makes rational drug design that target Ubc9 possible. Structure-based virtual drug screening has been used increasingly as the first step of drug design to select potential lead templates. This review analyzes all the interfaces between Ubc9 and its binding partners while also highlighting the possible targeting sites on Ubc9 best suited for virtual screening and drug design.
Export Options
About this article
Cite this article as:
Duan Xinyuan, Trent O. John and Ye Hong, Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152009787047716
DOI https://dx.doi.org/10.2174/187152009787047716 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Subject Index To Volume 7
Current Drug Targets Human Retinoblastoma Binding Protein 9, a Serine Hydrolase Implicated in Pancreatic Cancers
Protein & Peptide Letters Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling
Current Genomics IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets